Maze Therapeutics Business Summary

Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, milestone payments, and asset monetization, as it remains pre-revenue from commercial product sales. The company’s business model is centered on its proprietary Compass™ platform, which integrates human genetics, functional genomics, and data science to identify and advance small-molecule precision medicines. Its primary business segments focus on renal, cardiovascular, and related metabolic (CVRM) diseases, with lead clinical programs including MZE829 for APOL1-mediated kidney disease and MZE782 for chronic kidney disease and phenylketonuria. Maze competes directly with established players like Vertex Pharmaceuticals, Abivax, and Praxis Precision Medicines, positioning itself as a high-density precision medicine developer that differentiates through the use of genetic modifiers to de-risk drug discovery. The company was founded by a distinguished team of scientists and industry veterans, including Jason Coloma, Ph.D., Charles Homcy, M.D., and renowned geneticists Mark Daly, Stephen Elledge, Aaron Gitler, Sekar Kathiresan, and Jonathan Weissman. The current leadership team is led by CEO Jason Coloma, who previously served as a venture partner at Third Rock Ventures, alongside Harold Bernstein, M.D., Ph.D. (President, R&D and Chief Medical Officer), Misbah Tahir (Chief Financial Officer), and Atul Dandekar (Chief Strategy & Business Officer). The board is chaired by Hervé Hoppenot, former CEO of Incyte, who joined in late 2025. Maze is backed by a high-pedigree investor syndicate including Third Rock Ventures, ARCH Venture Partners, City Hill Ventures, and Alphabet Inc., maintaining a strong capital position following its 2025 IPO and subsequent private placements.